MonoFIX-VF, a new mono-component factor IX concentrate: a single-centre continuous-infusion study
Related Experiment Video
Updated: Sep 29, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
1Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK. gillian.evans@ernt.nhs.uk
Abstract:
MonoFIX-VF, a monocomponent factor IX concentrate, has replaced the use of Prothrombinex-HT as the treatment of choice for patients with factor IX deficiency in Australia. The haemostatic effect of MonoFIX-VF, administered by continuous infusion, was assessed in four subjects being treated for 10 bleeding episodes including five surgical procedures. MonoFIX-VF was found to be a safe and effective treatment for patients with haemophilia B.
Related Concept Videos
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Bioavailability Study Design: Single Versus Multiple Dose Studies
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Biopharmaceutical Factors Influencing Drug Product Design: Overview

